Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor

A study in rhesus monkeys

Thomas Geisbert, Lisa E. Hensley, Peter B. Jahrling, Tom Larsen, Joan B. Geisbert, Jason Paragas, Howard A. Young, Terry M. Fredeking, William E. Rote, George P. Vlasuk

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

Background: Infection with the Ebola virus induces overexpression of the procoagulant tissue factor in primate monocytes and macrophages, suggesting that inhibition of the tissue-factor pathway could ameliorate the effects of Ebola haemorrhagic fever. Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus. Methods: We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100% mortality. We administered recombinant nematode anticoagulant protein c2 (rNAPc2), a potent inhibitor of tissue factor-initiated blood coagulation, to the macaques either 10 min (n=6) or 24 h (n=3) after a high-dose lethal injection of Ebola virus. Three animals served as untreated Ebola virus-positive controls. Historical controls were also used in some analyses. Findings: Both treatment regimens prolonged survival time, with a 33% survival rate in each treatment group. Survivors are still alive and healthy after 9 months. All but one of the 17 controls died. The mean survival for the six rNAPc2-treated macaques that died was 11.7 days compared with 8.3 days for untreated controls (p=0.0184). rNAPc2 attenuated the coagulation response as evidenced by modulation of various important coagulation factors, including plasma D dimers, which were reduced in nearly all treated animals; less prominent fibrin deposits and intravascular thromboemboli were observed in tissues of some animals that succumbed to Ebola virus. Furthermore, rNAPc2 attenuated the proinflammatory response with lower plasma concentrations of interleukin 6 and monocyte chemoattractant protein-1 (MCP-1) noted in the treated than in the untreated macaques. Interpretation: Post-exposure protection with rNAPc2 against Ebola virus in primates provides a new foundation for therapeutic regimens that target the disease process rather than viral replication.

Original languageEnglish (US)
Pages (from-to)1953-1958
Number of pages6
JournalLancet
Volume362
Issue number9400
DOIs
StatePublished - Dec 13 2003
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Thromboplastin
Macaca mulatta
Macaca
Primates
Capital Punishment
Therapeutics
Blood Coagulation Factors
Survival
Chemokine CCL2
Blood Coagulation
Fibrin
Survivors
Monocytes
Interleukin-6
Survival Rate
Macrophages
Ancylostoma caninum anti-coagulant protein C2
recombinant FVIIa

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Geisbert, T., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., ... Vlasuk, G. P. (2003). Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet, 362(9400), 1953-1958. https://doi.org/10.1016/S0140-6736(03)15012-X

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor : A study in rhesus monkeys. / Geisbert, Thomas; Hensley, Lisa E.; Jahrling, Peter B.; Larsen, Tom; Geisbert, Joan B.; Paragas, Jason; Young, Howard A.; Fredeking, Terry M.; Rote, William E.; Vlasuk, George P.

In: Lancet, Vol. 362, No. 9400, 13.12.2003, p. 1953-1958.

Research output: Contribution to journalArticle

Geisbert, T, Hensley, LE, Jahrling, PB, Larsen, T, Geisbert, JB, Paragas, J, Young, HA, Fredeking, TM, Rote, WE & Vlasuk, GP 2003, 'Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys', Lancet, vol. 362, no. 9400, pp. 1953-1958. https://doi.org/10.1016/S0140-6736(03)15012-X
Geisbert, Thomas ; Hensley, Lisa E. ; Jahrling, Peter B. ; Larsen, Tom ; Geisbert, Joan B. ; Paragas, Jason ; Young, Howard A. ; Fredeking, Terry M. ; Rote, William E. ; Vlasuk, George P. / Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor : A study in rhesus monkeys. In: Lancet. 2003 ; Vol. 362, No. 9400. pp. 1953-1958.
@article{87480749fc8e4ebb8a5f718a7a7d9519,
title = "Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys",
abstract = "Background: Infection with the Ebola virus induces overexpression of the procoagulant tissue factor in primate monocytes and macrophages, suggesting that inhibition of the tissue-factor pathway could ameliorate the effects of Ebola haemorrhagic fever. Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus. Methods: We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100{\%} mortality. We administered recombinant nematode anticoagulant protein c2 (rNAPc2), a potent inhibitor of tissue factor-initiated blood coagulation, to the macaques either 10 min (n=6) or 24 h (n=3) after a high-dose lethal injection of Ebola virus. Three animals served as untreated Ebola virus-positive controls. Historical controls were also used in some analyses. Findings: Both treatment regimens prolonged survival time, with a 33{\%} survival rate in each treatment group. Survivors are still alive and healthy after 9 months. All but one of the 17 controls died. The mean survival for the six rNAPc2-treated macaques that died was 11.7 days compared with 8.3 days for untreated controls (p=0.0184). rNAPc2 attenuated the coagulation response as evidenced by modulation of various important coagulation factors, including plasma D dimers, which were reduced in nearly all treated animals; less prominent fibrin deposits and intravascular thromboemboli were observed in tissues of some animals that succumbed to Ebola virus. Furthermore, rNAPc2 attenuated the proinflammatory response with lower plasma concentrations of interleukin 6 and monocyte chemoattractant protein-1 (MCP-1) noted in the treated than in the untreated macaques. Interpretation: Post-exposure protection with rNAPc2 against Ebola virus in primates provides a new foundation for therapeutic regimens that target the disease process rather than viral replication.",
author = "Thomas Geisbert and Hensley, {Lisa E.} and Jahrling, {Peter B.} and Tom Larsen and Geisbert, {Joan B.} and Jason Paragas and Young, {Howard A.} and Fredeking, {Terry M.} and Rote, {William E.} and Vlasuk, {George P.}",
year = "2003",
month = "12",
day = "13",
doi = "10.1016/S0140-6736(03)15012-X",
language = "English (US)",
volume = "362",
pages = "1953--1958",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9400",

}

TY - JOUR

T1 - Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor

T2 - A study in rhesus monkeys

AU - Geisbert, Thomas

AU - Hensley, Lisa E.

AU - Jahrling, Peter B.

AU - Larsen, Tom

AU - Geisbert, Joan B.

AU - Paragas, Jason

AU - Young, Howard A.

AU - Fredeking, Terry M.

AU - Rote, William E.

AU - Vlasuk, George P.

PY - 2003/12/13

Y1 - 2003/12/13

N2 - Background: Infection with the Ebola virus induces overexpression of the procoagulant tissue factor in primate monocytes and macrophages, suggesting that inhibition of the tissue-factor pathway could ameliorate the effects of Ebola haemorrhagic fever. Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus. Methods: We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100% mortality. We administered recombinant nematode anticoagulant protein c2 (rNAPc2), a potent inhibitor of tissue factor-initiated blood coagulation, to the macaques either 10 min (n=6) or 24 h (n=3) after a high-dose lethal injection of Ebola virus. Three animals served as untreated Ebola virus-positive controls. Historical controls were also used in some analyses. Findings: Both treatment regimens prolonged survival time, with a 33% survival rate in each treatment group. Survivors are still alive and healthy after 9 months. All but one of the 17 controls died. The mean survival for the six rNAPc2-treated macaques that died was 11.7 days compared with 8.3 days for untreated controls (p=0.0184). rNAPc2 attenuated the coagulation response as evidenced by modulation of various important coagulation factors, including plasma D dimers, which were reduced in nearly all treated animals; less prominent fibrin deposits and intravascular thromboemboli were observed in tissues of some animals that succumbed to Ebola virus. Furthermore, rNAPc2 attenuated the proinflammatory response with lower plasma concentrations of interleukin 6 and monocyte chemoattractant protein-1 (MCP-1) noted in the treated than in the untreated macaques. Interpretation: Post-exposure protection with rNAPc2 against Ebola virus in primates provides a new foundation for therapeutic regimens that target the disease process rather than viral replication.

AB - Background: Infection with the Ebola virus induces overexpression of the procoagulant tissue factor in primate monocytes and macrophages, suggesting that inhibition of the tissue-factor pathway could ameliorate the effects of Ebola haemorrhagic fever. Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus. Methods: We used a rhesus macaque model of Ebola haemorrhagic fever, which produces near 100% mortality. We administered recombinant nematode anticoagulant protein c2 (rNAPc2), a potent inhibitor of tissue factor-initiated blood coagulation, to the macaques either 10 min (n=6) or 24 h (n=3) after a high-dose lethal injection of Ebola virus. Three animals served as untreated Ebola virus-positive controls. Historical controls were also used in some analyses. Findings: Both treatment regimens prolonged survival time, with a 33% survival rate in each treatment group. Survivors are still alive and healthy after 9 months. All but one of the 17 controls died. The mean survival for the six rNAPc2-treated macaques that died was 11.7 days compared with 8.3 days for untreated controls (p=0.0184). rNAPc2 attenuated the coagulation response as evidenced by modulation of various important coagulation factors, including plasma D dimers, which were reduced in nearly all treated animals; less prominent fibrin deposits and intravascular thromboemboli were observed in tissues of some animals that succumbed to Ebola virus. Furthermore, rNAPc2 attenuated the proinflammatory response with lower plasma concentrations of interleukin 6 and monocyte chemoattractant protein-1 (MCP-1) noted in the treated than in the untreated macaques. Interpretation: Post-exposure protection with rNAPc2 against Ebola virus in primates provides a new foundation for therapeutic regimens that target the disease process rather than viral replication.

UR - http://www.scopus.com/inward/record.url?scp=10744222633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744222633&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)15012-X

DO - 10.1016/S0140-6736(03)15012-X

M3 - Article

VL - 362

SP - 1953

EP - 1958

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9400

ER -